Chiron Corporation

Tocagen Inc.

Chiron Viagene, Inc.

Other

Denovo Biopharma LLC

University of California

University of Iowa Research Foundation

Novartis Vaccines & Diagnostics, Gmbh

Oxford Biomedica (UK) Limited

Douglas J Jolly

Harry E Gruber

James G Respess

Jack R Barber

Paul K Laikind

Thomas W Dubensky, Jr

John M Polo

Carlos E Ibanez

David A Driver

Christopher R Logg

Omar D Perez

Amy Lin

Stephen M W Chang

Stephen M Chang

Kay Olmstead

Derek G Ostertag

Harry E Guber

Beverly L Davidson

Barbara A Belli

Sunil D Chada

Joan M Robbins

Mordechai Bodner

Colleen Stein

Sybille L Sauter

John F Warner

Daniel C St Louis

Hwei-Sing Kwang

Jason A Heth

Tiffany Huang

Noriyuki Kasahara

Paul B McCray, Jr

Theodore Friedmann

Stephen Chang

Jiing-Kuan Yee

Daniel J Hogan

Nicholas J DePolo

David Chi-Tang Hsu

Ryan Burnett

William T L Lee

Judith Greengard

Kay Townsend

Joanne O'Dea

Steven Mw Chang

Andrew Hofacre

Wolfgang M Klump

Caty E DeJesus

Nobuhiko Emi

Guoshun Wang

Steven M Herrmann

Lee Will

Amy H Lin

This disclosure provides modified recombinant retroviruses comprisings containing a 2A-peptide or peptide-like coding sequence operably linked to a heterologous polynucleotide. The disclosure further relates to cells and vector expressing or comprising such vectors and methods of using such modified vectors in the treatment of disease and disorders.

Recombinant vectors comprising 2A peptide

The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.

Retroviral vector having immune-stimulating activity

The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorourcail in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.

Formulations of 5-fluorocytosine and uses thereof

This disclosure provides a retroviral replicating vector for gene delivery comprising a therapeutic cassette containing at least one mini-promoter linked to a gene to be expressed.

Retroviral vector with mini-promoter cassette

The disclosure provide cell lines and methods for the production of vectors and viral particles useful in gene therapy.

Producer cells for replication competent retroviral vectors

The disclosure provides an extended release formulation of 5-fluorocytosine. In another aspect, a method of treating a fungal disease is provided. The method comprises administering to a subject in need thereof a fungus-treating effective amount of a composition comprising 5-fluorocytosine. In yet another aspect, a method of treating a cancer is provided. The method comprises administering to a subject in need thereof a sufficient amount of an expression vector to induce expression of cytosine deaminase which is capable of converting 5-fluorocytosine to 5-fluorouracil in cells of the cancer and a cancer-treating effective amount of a composition comprising 5-fluorocytosine.

This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.

Recombinant vectors

Gene therapy vectors and cytosine deaminases

This disclosure relates to replication competent viral vectors for treating cell proliferative disorders. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

Compositions comprising gamma retrovirus vectors and methods of treating proliferative disorders

Provided are methods and compositions useful for detecting viral infection or contamination in a biological sample.

Retrovirus detection

This disclosure relates to a combination therapy of chemotherapeutics and/or radiosensitizing agents with a replication competent viral vectors for treating cell proliferative disorders and chemotherapeutic treatments. The disclosure further relates to the use of such replication competent viral vectors for delivery and expression of a heterologous nucleic acid in normal and diseased tissues and methods and compositions that facilitate such delivery and expression to tissues in vivo and in vitro. The disclosure further relates to replication competent retroviral vectors for these uses and in conjunction with methods and compositions that facilitate in vivo therapeutics.

Cancer combination therapy and recombinant vectors

Growing community of inventors

Encinitas, CA, United States of America

Douglas J Jolly